IgG persistence showed weak clinical aspects in chronic schistosomiasis patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2023
14 08 2023
Historique:
received:
13
02
2023
accepted:
04
08
2023
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Schistosomiasis is a chronic parasitic disease, which affects the quality of daily life of patients and imposes a huge burden on society. Hepatic fibrosis in response to continuous insult of eggs to the liver is a significant cause of morbidity and mortality. However, the mechanisms of hepatic fibrosis in schistosomiasis are largely undefined. The purpose of our study is to detect the indicator to hepatic fibrosis in schistosomiasis. A total of 488 patients with chronic schistosomiasis japonica were enrolled in our study. The patients were divided into two groups according to liver ultrasound examination, which could indicate liver fibrosis of schistosomiasis with unique reticular changes. Logistic regression analysis showed that globulin, albumin/globulin, GGT levels and anti-Schistosoma IgG were independently associated with liver fibrosis in patients with schistosomiasis and IgG was the largest association of liver fibrosis (OR 2.039, 95% CI 1.293-3.213). We further compared IgG+ patients with IgG- patients. IgG+ patients (ALT 25 U/L, GGT 31 U/L) slightly higher than IgG- patients (ALT 22 U/L, GGT 26 U/L) in ALT and GGT. However, the fibrosis of liver in IgG+ patients (Grade II(19.7%), Grade III(7.3%)) were more severe than that in IgG- patients(Grade II(12.5%), Grade III(2.9%)) according to the grade of liver ultrasonography. Our results showed anti-Schistosoma IgG was independently associated with liver fibrosis in patients with chronic schistosomiasis japonica and patients with persistent anti-Schistosoma IgG might have more liver fibrosis than negative patients despite no obvious clinical signs or symptoms.
Identifiants
pubmed: 37580417
doi: 10.1038/s41598-023-40082-z
pii: 10.1038/s41598-023-40082-z
pmc: PMC10425409
doi:
Substances chimiques
Immunoglobulin G
0
Antibodies, Helminth
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13222Informations de copyright
© 2023. Springer Nature Limited.
Références
Lo, N. C. et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00221-3 (2022).
doi: 10.1016/S1473-3099(22)00221-3
pubmed: 35594896
Isaiah, P. M., Sólveig Palmeirim, M. & Steinmann, P. Epidemiology of pediatric schistosomiasis in hard-to-reach areas and populations: A scoping review. Infect. Dis. Poverty 12, 37. https://doi.org/10.1186/s40249-023-01088-x (2023).
doi: 10.1186/s40249-023-01088-x
pubmed: 37069632
pmcid: 10108517
Luo, C. et al. Mapping schistosomiasis risk in Southeast Asia: A systematic review and geospatial analysis. Int. J. Epidemiol. https://doi.org/10.1093/ije/dyac227 (2022).
doi: 10.1093/ije/dyac227
pubmed: 35445260
LoVerde, P. T. et al. Rational approach to drug discovery for human schistosomiasis. Int. J. Parasitol. Drugs Drug Resist. 16, 140–147. https://doi.org/10.1016/j.ijpddr.2021.05.002 (2021).
doi: 10.1016/j.ijpddr.2021.05.002
pubmed: 34111649
pmcid: 8193065
Gryseels, B., Polman, K., Clerinx, J. & Kestens, L. Human schistosomiasis. Lancet 368, 1106–1118 (2006).
doi: 10.1016/S0140-6736(06)69440-3
pubmed: 16997665
McManus, D. P. et al. Schistosomiasis. Nat. Rev. Dis. Prim. 4, 13. https://doi.org/10.1038/s41572-018-0013-8 (2018).
doi: 10.1038/s41572-018-0013-8
pubmed: 30093684
Vale, N. et al. Praziquantel for Schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.02582-16 (2017).
doi: 10.1128/AAC.02582-16
pubmed: 28264841
pmcid: 5404606
Kamdem, S. D., Moyou-Somo, R., Brombacher, F. & Nono, J. K. Host regulators of liver fibrosis during human schistosomiasis. Front. Immunol. 9, 2781. https://doi.org/10.3389/fimmu.2018.02781 (2018).
doi: 10.3389/fimmu.2018.02781
pubmed: 30546364
pmcid: 6279936
Hams, E., Aviello, G. & Fallon, P. G. The schistosoma granuloma: Friend or foe?. Front. Immunol. 4, 89. https://doi.org/10.3389/fimmu.2013.00089 (2013).
doi: 10.3389/fimmu.2013.00089
pubmed: 23596444
pmcid: 3625856
Chuah, C., Jones, M. K., Burke, M. L., McManus, D. P. & Gobert, G. N. Cellular and chemokine-mediated regulation in schistosome-induced hepatic pathology. Trends Parasitol. 30, 141–150. https://doi.org/10.1016/j.pt.2013.12.009 (2014).
doi: 10.1016/j.pt.2013.12.009
pubmed: 24433721
Shekhar, K. C. Tropical gastrointestinal disease: Hepatosplenic schistosomiasis–pathological, clinical and treatment review. Singap. Med. J. 35, 616–621 (1994).
Li, Y. et al. Severe hepatosplenic schistosomiasis: Clinicopathologic study of 102 cases undergoing splenectomy. Hum. Pathol. 42, 111–119. https://doi.org/10.1016/j.humpath.2010.05.020 (2011).
doi: 10.1016/j.humpath.2010.05.020
pubmed: 20970162
Zheng, B. et al. T lymphocyte-mediated liver immunopathology of schistosomiasis. Front. Immunol. 11, 61. https://doi.org/10.3389/fimmu.2020.00061 (2020).
doi: 10.3389/fimmu.2020.00061
pubmed: 32132991
pmcid: 7040032
Liu, C. et al. Immunopathology in schistosomiasis is regulated by TLR2,4- and IFN-γ-activated MSC through modulating Th1/Th2 responses. Stem Cell Res. Ther. 11, 217. https://doi.org/10.1186/s13287-020-01735-2 (2020).
doi: 10.1186/s13287-020-01735-2
pubmed: 32503644
pmcid: 7275460
Zhang, Y. et al. A preliminary investigation into the immune cell landscape of schistosome-associated liver fibrosis in humans. Immunol. Cell Biol. 99, 803–813. https://doi.org/10.1111/imcb.12490 (2021).
doi: 10.1111/imcb.12490
pubmed: 34355810
pmcid: 8456952
Chensue, S. W., Ruth, J. H., Warmington, K., Lincoln, P. & Kunkel, S. L. In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation. J. Immunol. 155, 3546–3551 (1995).
doi: 10.4049/jimmunol.155.7.3546
pubmed: 7561051
Schwartz, C., Oeser, K., da Prazeres, C. C., Layland, L. E. & Voehringer, D. T cell-derived IL-4/IL-13 protects mice against fatal Schistosoma mansoni infection independently of basophils. J Immunol 193, 3590–3599. https://doi.org/10.4049/jimmunol.1401155 (2014).
doi: 10.4049/jimmunol.1401155
pubmed: 25172500
Jankovic, D. et al. CD4+ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling. J. Exp. Med. 187, 619–629 (1998).
doi: 10.1084/jem.187.4.619
pubmed: 9463412
pmcid: 2212140
Vereecken, K. et al. Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni. Trop. Med. Int. Health 12, 431–444 (2007).
doi: 10.1111/j.1365-3156.2006.01805.x
pubmed: 17313515
Fairfax, K. C. et al. IL-10R blockade during chronic schistosomiasis mansoni results in the loss of B cells from the liver and the development of severe pulmonary disease. PLoS Pathog. 8, e1002490. https://doi.org/10.1371/journal.ppat.1002490 (2012).
doi: 10.1371/journal.ppat.1002490
pubmed: 22291593
pmcid: 3266936
Chen, X. et al. Elevated serum antibody against Schistosoma japonicum HSP60 as a promising biomarker for liver pathology in schistosomiasis. Sci Rep 7, 7765. https://doi.org/10.1038/s41598-017-08283-5 (2017).
doi: 10.1038/s41598-017-08283-5
pubmed: 28798366
pmcid: 5552731
Ohta, N., Hosaka, Y., Minai, M., Hayashi, M. & Miki, Y. Disappearance of specific antibodies in patients with chronic schistosomiasis japonica by treatment with praziquantel. Jpn. J. Med. Sci. Biol. 42, 31–38 (1989).
doi: 10.7883/yoken1952.42.31
pubmed: 2506387
Van’t Wout, A. B. et al. Schistosome circulating anodic antigen in serum of individuals infected with Schistosoma japonicum from the Philippines before and after chemotherapy with praziquantel. Trans. R. Soc. Trop. Med. Hyg. 86, 410–413 (1992).
doi: 10.1016/0035-9203(92)90243-6
pubmed: 1440819
Ji, F. et al. B cell response is required for granuloma formation in the early infection of Schistosoma japonicum. PLoS ONE 3, e1724. https://doi.org/10.1371/journal.pone.0001724 (2008).
doi: 10.1371/journal.pone.0001724
pubmed: 18320044
pmcid: 2248706
Negrão-Corrêa, D. et al. Association of Schistosoma mansoni-specific IgG and IgE antibody production and clinical schistosomiasis status in a rural area of Minas Gerais, Brazil. PLoS ONE 9, e88042. https://doi.org/10.1371/journal.pone.0088042 (2014).
doi: 10.1371/journal.pone.0088042
pubmed: 24505371
pmcid: 3913716
Saad, A. M. et al. Oesophageal varices in a region of the Sudan endemic for Schistosoma mansoni. Br. J. Surg. 78, 1252–1253 (1991).
doi: 10.1002/bjs.1800781033
pubmed: 1958998
Hussain, S., Hawass, N. D. & Zaidi, A. J. Ultrasonographic diagnosis of schistosomal periportal fibrosis. J. Ultrasound Med. 3, 449–452 (1984).
doi: 10.7863/jum.1984.3.10.449
pubmed: 6387168
Salvana, E. M. T. & King, C. H. Schistosomiasis in travelers and immigrants. Curr. Infect. Dis. Rep. 10, 42–49 (2008).
doi: 10.1007/s11908-008-0009-8
pubmed: 18377815
Wang, X., Wang, W. & Wang, P. Long-term effectiveness of the integrated schistosomiasis control strategy with emphasis on infectious source control in China: A 10-year evaluation from 2005 to 2014. Parasitol. Res. 116, 521–528. https://doi.org/10.1007/s00436-016-5315-8 (2017).
doi: 10.1007/s00436-016-5315-8
pubmed: 27812902
Ohmae, H., Sy, O. S., Chigusa, Y. & Portillo, G. P. Imaging diagnosis of schistosomiasis japonica–the use in Japan and application for field study in the present endemic area. Parasitol. Int. 52, 385–393 (2003).
doi: 10.1016/S1383-5769(03)00055-2
pubmed: 14665397
Liu, X.-D., Wu, J.-L., Liang, J., Zhang, T. & Sheng, Q.-S. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J. Gastroenterol. 18, 2784–2792. https://doi.org/10.3748/wjg.v18.i22.2784 (2012).
doi: 10.3748/wjg.v18.i22.2784
pubmed: 22719186
pmcid: 3374981
Zeng, D.-W. et al. A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: A multicenter retrospective study. Ther. Adv. Gastroenterol. 14, 17562848211010676. https://doi.org/10.1177/17562848211010675 (2021).
doi: 10.1177/17562848211010675
Maizels, R. M. & Yazdanbakhsh, M. Immune regulation by helminth parasites: Cellular and molecular mechanisms. Nat. Rev. Immunol. 3, 733–744 (2003).
doi: 10.1038/nri1183
pubmed: 12949497
Dunne, D. W., Butterworth, A. E., Fulford, A. J., Ouma, J. H. & Sturrock, R. F. Human IgE responses to Schistosoma mansoni and resistance to reinfection. Mem. Inst. Oswaldo Cruz 87(Suppl 4), 99 (1992).
doi: 10.1590/S0074-02761992000800014
pubmed: 1343933
Liu, Z., Zhang, L., Liang, Y. & Lu, L. Pathology and molecular mechanisms of Schistosoma japonicum-associated liver fibrosis. Front. Cell Infect. Microbiol. 12, 1035765. https://doi.org/10.3389/fcimb.2022.1035765 (2022).
doi: 10.3389/fcimb.2022.1035765
pubmed: 36389166
pmcid: 9650140
Warren, K. S. et al. Morbidity in schistosomiasis japonica in relation to intensity of infection. A study of two rural brigades in Anhui Province, China. N. Engl. J. Med. 309, 1533–1539 (1983).
doi: 10.1056/NEJM198312223092501
pubmed: 6656848
Coutinho, E. M. et al. Repeated infections with Schistosoma mansoni and liver fibrosis in undernourished mice. Acta Trop. 101, 15–24 (2007).
doi: 10.1016/j.actatropica.2006.03.006
pubmed: 17194437
Carlton, E. J., Hubbard, A., Wang, S. & Spear, R. C. Repeated Schistosoma japonicum infection following treatment in two cohorts: Evidence for host susceptibility to helminthiasis?. PLoS Negl. Trop. Dis. 7, e2098. https://doi.org/10.1371/journal.pntd.0002098 (2013).
doi: 10.1371/journal.pntd.0002098
pubmed: 23505589
pmcid: 3591324
Doughty, B. L., Ottesen, E. A., Nash, T. E. & Phillips, S. M. Delayed hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro. III. Granuloma formation and modulation in human schistosomiasis mansoni. J. Immunol. 133, 993–997 (1984).
doi: 10.4049/jimmunol.133.2.993
pubmed: 6234365
Lo, N. C. et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect. Dis. 22, e327–e335. https://doi.org/10.1016/S1473-3099(22)00221-3 (2022).
doi: 10.1016/S1473-3099(22)00221-3
pubmed: 35594896
Siqueira, L. D. P. et al. Schistosomiasis: Drugs used and treatment strategies. Acta Trop. 176, 179–187. https://doi.org/10.1016/j.actatropica.2017.08.002 (2017).
doi: 10.1016/j.actatropica.2017.08.002
pubmed: 28803725
Chen, C. et al. Reviews and advances in diagnostic research on Schistosoma japonicum. Acta Trop. 213, 105743. https://doi.org/10.1016/j.actatropica.2020.105743 (2021).
doi: 10.1016/j.actatropica.2020.105743
pubmed: 33159894
Zhou, Y.-B., Zheng, H.-M. & Jiang, Q.-W. A diagnostic challenge for Schistosomiasis japonica in China: Consequences on praziquantel-based morbidity control. Parasit. Vectors 4, 194. https://doi.org/10.1186/1756-3305-4-194 (2011).
doi: 10.1186/1756-3305-4-194
pubmed: 21981948
pmcid: 3195757
Cairo Working Group. The use of diagnostic ultrasound in schistosomiasis–attempts at standardization of methodology. Acta Trop. 51, 45–63 (1992).
doi: 10.1016/0001-706X(92)90020-X
Hu, F. et al. The dynamics of hepatic fibrosis related to schistosomiasis and its risk factors in a cohort of China. Pathogens https://doi.org/10.3390/pathogens10121532 (2021).
doi: 10.3390/pathogens10121532
pubmed: 34959583
pmcid: 8707762
Zhu, Y.-C. Immunodiagnosis and its role in schistosomiasis control in China: A review. Acta Trop. 96, 130–136 (2005).
doi: 10.1016/j.actatropica.2005.07.007
pubmed: 16143288